Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.75
BIIB's Cash-to-Debt is ranked lower than
83% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. BIIB: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.54 Max: 19.58
Current: 0.75
0.25
19.58
Equity-to-Asset 0.53
BIIB's Equity-to-Asset is ranked lower than
67% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BIIB: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.73 Max: 0.84
Current: 0.53
0.48
0.84
Interest Coverage 19.81
BIIB's Interest Coverage is ranked lower than
82% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 19.81 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.25  Med: 42.88 Max: 134.66
Current: 19.81
19.25
134.66
Piotroski F-Score: 5
Altman Z-Score: 5.94
Beneish M-Score: -2.50
WACC vs ROIC
5.90%
28.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 44.99
BIIB's Operating Margin % is ranked higher than
96% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. BIIB: 44.99 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 24.59  Med: 33.48 Max: 45.44
Current: 44.99
24.59
45.44
Net Margin % 32.34
BIIB's Net Margin % is ranked higher than
93% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. BIIB: 32.34 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 32.34
19.11
32.95
ROE % 33.44
BIIB's ROE % is ranked higher than
96% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. BIIB: 33.44 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 10.06  Med: 20.75 Max: 35.15
Current: 33.44
10.06
35.15
ROA % 17.36
BIIB's ROA % is ranked higher than
95% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. BIIB: 17.36 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 7.43  Med: 14.4 Max: 22.42
Current: 17.36
7.43
22.42
ROC (Joel Greenblatt) % 162.05
BIIB's ROC (Joel Greenblatt) % is ranked higher than
95% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. BIIB: 162.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.17  Med: 90.54 Max: 189.7
Current: 162.05
54.17
189.7
3-Year Revenue Growth Rate 21.60
BIIB's 3-Year Revenue Growth Rate is ranked higher than
74% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BIIB: 21.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.9  Med: 24.1 Max: 78.2
Current: 21.6
-1.9
78.2
3-Year EBITDA Growth Rate 28.10
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BIIB: 28.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.6  Med: 28.1 Max: 82.3
Current: 28.1
-18.6
82.3
3-Year EPS without NRI Growth Rate 29.40
BIIB's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. BIIB: 29.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66  Med: 29.4 Max: 205.2
Current: 29.4
-66
205.2
GuruFocus has detected 2 Warning Signs with Biogen Inc $BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 10-Y Financials

Financials (Next Earnings Date: 2017-04-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BIIB Guru Trades in Q1 2016

Pioneer Investments 880 sh (New)
Ronald Muhlenkamp 23,853 sh (New)
Jim Simons 127,661 sh (New)
Lee Ainslie 9,370 sh (New)
Joel Greenblatt 298,673 sh (+253.14%)
John Paulson 118,400 sh (+227.07%)
Richard Snow 91,801 sh (+127.85%)
Ron Baron 16,047 sh (+56.71%)
Jeff Auxier 9,015 sh (+25.30%)
Steven Cohen 102,200 sh (+17.88%)
First Eagle Investment 224,585 sh (+15.83%)
PRIMECAP Management 16,246,726 sh (+2.76%)
Mario Gabelli 4,810 sh (+0.10%)
Murray Stahl 7,705 sh (unchged)
Vanguard Health Care Fund 3,810,023 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 200,000 sh (unchged)
Signature Select Canadian Fund Sold Out
John Buckingham 16,809 sh (-3.34%)
Mairs and Power 1,025 sh (-6.39%)
Frank Sands 3,141,109 sh (-6.72%)
Ray Dalio 23,106 sh (-7.97%)
Ken Fisher 90,405 sh (-18.17%)
Andreas Halvorsen 230,947 sh (-37.39%)
Paul Tudor Jones 1,000 sh (-77.11%)
Jeremy Grantham 1,380 sh (-98.60%)
» More
Q2 2016

BIIB Guru Trades in Q2 2016

HOTCHKIS & WILEY 229,000 sh (New)
Sarah Ketterer 489,263 sh (New)
David Dreman 150 sh (New)
Paul Tudor Jones 18,123 sh (+1712.30%)
Andreas Halvorsen 3,210,507 sh (+1290.15%)
Richard Snow 211,561 sh (+130.46%)
Ray Dalio 51,461 sh (+122.72%)
Jeff Auxier 17,985 sh (+99.50%)
First Eagle Investment 332,760 sh (+48.17%)
Pioneer Investments 1,099 sh (+24.89%)
Joel Greenblatt 368,095 sh (+23.24%)
Ron Baron 19,621 sh (+22.27%)
Lee Ainslie 11,010 sh (+17.50%)
Ken Fisher 101,919 sh (+12.74%)
John Paulson 123,100 sh (+3.97%)
Vanguard Health Care Fund 3,956,663 sh (+3.85%)
John Buckingham 16,831 sh (+0.13%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Mario Gabelli 4,797 sh (-0.27%)
Ronald Muhlenkamp 23,703 sh (-0.63%)
PRIMECAP Management 16,024,861 sh (-1.37%)
Frank Sands 2,970,230 sh (-5.44%)
Jim Simons 40,400 sh (-68.35%)
Eaton Vance Worldwide Health Sciences Fund 176,000 sh (-12.00%)
» More
Q3 2016

BIIB Guru Trades in Q3 2016

Richard Pzena 642 sh (New)
Eric Mindich 64,000 sh (New)
Steven Cohen 117,548 sh (New)
George Soros 1,994 sh (New)
Paul Tudor Jones 125,668 sh (+593.42%)
Jim Simons 238,261 sh (+489.75%)
John Paulson 308,000 sh (+150.20%)
First Eagle Investment 457,260 sh (+37.41%)
HOTCHKIS & WILEY 306,100 sh (+33.67%)
Jeff Auxier 22,635 sh (+25.85%)
David Dreman 150 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Paul Tudor Jones 20,000 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Ronald Muhlenkamp 23,478 sh (-0.95%)
John Buckingham 16,642 sh (-1.12%)
Ken Fisher 100,718 sh (-1.18%)
PRIMECAP Management 15,693,905 sh (-2.07%)
Richard Snow 203,525 sh (-3.80%)
Vanguard Health Care Fund 3,759,703 sh (-4.98%)
Lee Ainslie 10,380 sh (-5.72%)
Frank Sands 2,789,266 sh (-6.09%)
Sarah Ketterer 404,444 sh (-17.34%)
Andreas Halvorsen 2,186,336 sh (-31.90%)
Joel Greenblatt 245,468 sh (-33.31%)
Pioneer Investments 665 sh (-39.49%)
Mario Gabelli 1,897 sh (-60.45%)
Ron Baron 6,577 sh (-66.48%)
Ray Dalio 900 sh (-98.25%)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (-5.40%)
» More
Q4 2016

BIIB Guru Trades in Q4 2016

John Hussman 350 sh (New)
John Burbank 5,904 sh (New)
Eric Mindich 327,882 sh (+412.32%)
David Dreman 602 sh (+301.33%)
Jim Simons 707,495 sh (+196.94%)
Lee Ainslie 10,880 sh (+4.82%)
Vanguard Health Care Fund 3,841,803 sh (+2.18%)
John Buckingham 16,934 sh (+1.75%)
Ken Fisher 101,887 sh (+1.16%)
Ron Baron 6,625 sh (+0.73%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Eric Mindich 400,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (unchged)
Pioneer Investments Sold Out
Richard Pzena Sold Out
Ray Dalio Sold Out
Sarah Ketterer Sold Out
George Soros Sold Out
PRIMECAP Management 15,584,387 sh (-0.70%)
Ronald Muhlenkamp 23,279 sh (-0.85%)
Mario Gabelli 1,872 sh (-1.32%)
Joel Greenblatt 240,311 sh (-2.10%)
Richard Snow 192,361 sh (-5.49%)
HOTCHKIS & WILEY 286,800 sh (-6.31%)
Frank Sands 2,578,909 sh (-7.54%)
Andreas Halvorsen 1,918,812 sh (-12.24%)
Murray Stahl 6,655 sh (-13.63%)
First Eagle Investment 257,025 sh (-43.79%)
Steven Cohen 53,542 sh (-54.45%)
John Paulson 52,200 sh (-83.05%)
Paul Tudor Jones 7,815 sh (-93.78%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:SHPGF, OTCPK:CSLLY, NAS:REGN, OTCPK:NONOF, NAS:GILD, NAS:CELG, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BMRN, OTCPK:GIKLY, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMY, NAS:TSRO, NAS:SGEN, NAS:ALKS, NAS:JAZZ, NAS:UTHR » details
Traded in other countries:BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.

Biogen Inc was founded in 1978 in the state if Delaware. In March 2015, its name changed from Biogen Idec Inc. to Biogen Inc. It is a biotechnology company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.

Top Ranked Articles about Biogen Inc

Health Care Companies Showing Good Defensive Potential Deep analysis of historical financial trends for health care companies
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson (NYSE:JNJ), Biogen Inc. (NASDAQ:BIIB) and VCA Inc. (NASDAQ:WOOF), generally had strong financial strength and gross margins. Read more...
Sarah Ketterer Takes 3 Positions in 2nd Quarter Guru reports quarterly portfolio
Sarah Ketterer (Trades, Portfolio), founder and CEO of Causeway Capital Management LLC, creates long-term capital growth for her shareholders through value-oriented investing. As discussed in the fund’s prospectus, Ketterer prefers stocks that have low valuations and good financial strength. During the second quarter, the fund invested in three new companies, including major Chinese online media company Baidu Inc. (NASDAQ:BIDU). Read more...
Joel Greenblatt Bets on eBay, Intel, Biogen The investor's top buys in the 1st quarter
Joel Greenblatt (Trades, Portfolio) is founder and managing partner of Gotham Asset Management LLC. He is known for the invention of Magic Formula Investing and founded the New York Securities Auction Corporation (NYSAC). Read more...
Richard Snow Boosts Biogen, Keysight Technologies The largest increases by the guru during the 1st quarter
Richard Snow (Trades, Portfolio) is founder of Snow Capital. Snow began his career investing the proceeds from the sale of the Snow family businesses. During the first quarter he bought the following shares: Read more...
10 Years of Strong Returns: Priceline, Biogen Companies with high profitability and strong returns
According to GuruFocus' All-in-One Screener, the following stocks have had strong performances over the last 10 years with high and steady returns as well as profitability. EPS has also grown steadily with the companies' revenues. Most of these companies have great cash-to-debt ratios. Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.84
BIIB's PE Ratio is ranked higher than
69% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. BIIB: 16.84 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 23.23 Max: 439.5
Current: 16.84
10.8
439.5
Forward PE Ratio 13.70
BIIB's Forward PE Ratio is ranked higher than
72% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. BIIB: 13.70 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.84
BIIB's PE Ratio without NRI is ranked higher than
70% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. BIIB: 16.84 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 23.23 Max: 488.33
Current: 16.84
10.8
488.33
Price-to-Owner-Earnings 19.01
BIIB's Price-to-Owner-Earnings is ranked higher than
63% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. BIIB: 19.01 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.96  Med: 22.7 Max: 155.47
Current: 19.01
9.96
155.47
PB Ratio 5.06
BIIB's PB Ratio is ranked lower than
65% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BIIB: 5.06 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 3.91 Max: 8.84
Current: 5.06
1.71
8.84
PS Ratio 5.48
BIIB's PS Ratio is ranked higher than
70% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. BIIB: 5.48 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.59  Med: 5.48 Max: 11
Current: 5.48
2.59
11
Price-to-Free-Cash-Flow 16.47
BIIB's Price-to-Free-Cash-Flow is ranked higher than
64% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. BIIB: 16.47 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.36  Med: 19.39 Max: 36.19
Current: 16.47
9.36
36.19
Price-to-Operating-Cash-Flow 13.85
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
67% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. BIIB: 13.85 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.32  Med: 16.36 Max: 32.51
Current: 13.85
7.32
32.51
EV-to-EBIT 12.49
BIIB's EV-to-EBIT is ranked higher than
61% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. BIIB: 12.49 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 16.3 Max: 62.7
Current: 12.49
7.5
62.7
EV-to-EBITDA 11.01
BIIB's EV-to-EBITDA is ranked higher than
62% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. BIIB: 11.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 12.6 Max: 24.9
Current: 11.01
6.1
24.9
PEG Ratio 0.59
BIIB's PEG Ratio is ranked higher than
85% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. BIIB: 0.59 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.85 Max: 35.41
Current: 0.59
0.32
35.41
Shiller PE Ratio 36.54
BIIB's Shiller PE Ratio is ranked higher than
64% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. BIIB: 36.54 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 29.59  Med: 77.07 Max: 506.33
Current: 36.54
29.59
506.33
Current Ratio 2.55
BIIB's Current Ratio is ranked lower than
68% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BIIB: 2.55 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 2.84 Max: 17.39
Current: 2.55
1.08
17.39
Quick Ratio 2.26
BIIB's Quick Ratio is ranked lower than
68% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. BIIB: 2.26 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 2.54 Max: 16.79
Current: 2.26
0.97
16.79
Days Inventory 240.21
BIIB's Days Inventory is ranked lower than
78% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BIIB: 240.21 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 240.21
219.47
266.3
Days Sales Outstanding 45.96
BIIB's Days Sales Outstanding is ranked higher than
63% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. BIIB: 45.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 45.32 Max: 48.62
Current: 45.96
39.79
48.62
Days Payable 69.07
BIIB's Days Payable is ranked higher than
57% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. BIIB: 69.07 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 69.07  Med: 98.14 Max: 148.21
Current: 69.07
69.07
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. BIIB: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -31  Med: 4.9 Max: 30.9
Current: 3
-31
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.21
BIIB's Price-to-Tangible-Book is ranked lower than
86% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. BIIB: 13.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.66  Med: 6.99 Max: 24.7
Current: 13.21
2.66
24.7
Price-to-Intrinsic-Value-Projected-FCF 1.64
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. BIIB: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.87  Med: 2.12 Max: 23.94
Current: 1.64
0.87
23.94
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.59
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
76% of the 21 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BIIB: 0.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.00
BIIB's Price-to-Median-PS-Value is ranked lower than
54% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BIIB: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.08 Max: 5.33
Current: 1
0.43
5.33
Price-to-Peter-Lynch-Fair-Value 0.67
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
87% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. BIIB: 0.67 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.34 Max: 18.88
Current: 0.67
0.59
18.88
Price-to-Graham-Number 3.14
BIIB's Price-to-Graham-Number is ranked lower than
62% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. BIIB: 3.14 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.66  Med: 3.09 Max: 18.53
Current: 3.14
1.66
18.53
Earnings Yield (Greenblatt) % 8.04
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. BIIB: 8.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 6.1 Max: 13.4
Current: 8.04
1.6
13.4
Forward Rate of Return (Yacktman) % 34.70
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
79% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. BIIB: 34.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -4.4  Med: 27.9 Max: 45.7
Current: 34.7
-4.4
45.7

More Statistics

Revenue (TTM) (Mil) $11,449
EPS (TTM) $ 16.94
Beta0.50
Short Percentage of Float0.87%
52-Week Range $205.43 - 307.33
Shares Outstanding (Mil)215.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11,678 12,384 14,178
EPS ($) 20.69 21.93 23.90
EPS without NRI ($) 20.69 21.93 23.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.43%
Dividends per Share ($)
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Feb 15 2017 
8 Stocks Trading Below Peter Lynch Value Jan 23 2017 
7 Stocks for 2017 Jan 20 2017 
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
John Paulson Continues to Buy These 8 Stocks Dec 23 2016 
Health Care Companies Showing Good Defensive Potential Dec 22 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
Paul Tudor Jones Exits EMC, Boosts Facebook, PepsiCo, Biogen Nov 23 2016 
Jeff Auxier Expands Holdings in Chemical and Biotech Companies Nov 21 2016 

More From Other Websites
Teva Is Expected to See a Fall in Its Profit Margins in 2017 Feb 23 2017
​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A Feb 21 2017
Celgene MS Drug Reports Positive Phase 3 Data Feb 20 2017
This Keeps Driving Sanofi’s Growth Feb 20 2017
Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment Feb 20 2017
​Shkreli defends drug prices, spars with protesters at heated UMass Boston event Feb 16 2017
Tesaro sees a $5B market opportunity for its cancer drug Feb 16 2017
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback Feb 16 2017
Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 15 2017
Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next? Feb 15 2017
Merck Halts Late-Stage Alzheimer’s Drug Trial Feb 15 2017
Bioverativ's hemophilia hopes Feb 15 2017
Regeneron: It's All Riding On Dupixent Feb 13 2017
Biogen’s Spinraza Faces Insurance Coverage Hurdles Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)